These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10101692)

  • 1. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
    Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
    J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 5. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 6. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
    Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'.
    Montalescot G
    Eur Heart J; 2002 Feb; 23(4):259-60. PubMed ID: 11812056
    [No Abstract]   [Full Text] [Related]  

  • 12. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 14. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
    Malhotra S; Mishra NK; Sinha RS; Gupta B
    J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
    Kereiakes DJ
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade.
    Armstrong PW
    CMAJ; 1999 Nov; 161(11):1423-4. PubMed ID: 10906900
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.